Study identifier:D6030C00001
ClinicalTrials.gov identifier:NCT02228369
EudraCT identifier:N/A
CTIS identifier:N/A
A Phase I, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumour Activity of AZD3759 or AZD9291 in Patients with EGFR Mutation Positive Advanced Stage Non Small Cell Lung Cancer (NSCLC)
EGFR Mutation Positive Advanced Non Small Cell Lung Cancer
Phase 1
No
AZD3759, AZD9291
All
108
Interventional
18 Years - 130 Years
Allocation: Non-randomized
Endpoint Classification: Safety/Efficacy
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Verified 01 Jan 2021 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: Daily dose of AZD3759 Daily oral dose of AZD3759 | Drug: AZD3759 Starting dose 50 mg, administered twice daily. If tolerated subsequent cohorts will test increasing doses of AZD3759, until a maximum tolerated dose or an effective dose is defined Other Name: NA |
Experimental: Daily Dose of AZD9291 Daily oral dose of AZD9291 | Drug: AZD9291 AZD9291 160mg once daily |